We Understand the Value of Strong Collaborations
Poxel has built a solid foundation in the field of metabolic diseases, both validated through significant collaborations with strong partners in the industry and academia. We are committed to maximizing the therapeutic and commercial potential of our pipeline. By combining our strong internal clinical development expertise in metabolic diseases with external partners, we can create powerful synergies and advance our goal to ultimately provide better treatment options for patients.
Our Industry Collaborators
- Sumitomo Dainippon Pharma
- Roivant Sciences
- DeuteRx LLC
- Enyo Pharma
We have a strategic development and commercialization agreement with Sumitomo Dainippon Pharma for the development and commercialization of Imeglimin in Japan, China and 11 other East and Southeast Asian countries. In Japan, we have successfully completed the Phase 3 TIMES program for the treatment of type 2 diabetes and the Japanese New Drug Application is on track for submission in 2020 currently under regulatory review with a product launch anticipated in Sumitomo Dainippon Pharma fiscal year 2021. Sumitomo Dainippon Pharma will commercialize Imeglimin for this market. In China, South Korea, Taiwan and nine other East and Southeast Asian countries including Indonesia, Vietnam, Thailand, Malaysia, the Philippines, Singapore, Myanmar, Cambodia, and Laos, Sumitomo Dainippon Pharma will be solely responsible for the development and commercialization of Imeglimin.
We have a strategic development and license agreement with Roivant Sciences for Imeglimin in the U.S., Europe, and other countries worldwide that are not covered under the Sumitomo Dainippon Pharma agreement. As of November 20, 2020, Metavant is exploring options for a potential out-licensing of Imeglimin rights and intends to return Imeglimin rights to Poxel if they are unable to reach an agreement on material terms by mid-January 2021.
Through an agreement with DeuteRx LLC, we acquired exclusive worldwide rights to PXL065, which has successfully completed Phase 1 development and has is advanceding into a streamlinedingle, comprehensive Phase 2 study (DESTINY 1) for the treatment of NASH. As part of the agreement with DeuteRx, we also acquired a portfolio of additional deuterated drug candidates for metabolic, specialty and rare diseases.
We have a licensing agreement with Enyo Pharma for our FXR (farnesoid X receptor) agonist. Enyo has completed a Phase 1 study and they are currently conducting Phase 2 trials in Hepatitis B and NASH.
Our Academic Collaborators
- CarMeN Laboratoire de recherche Cardiovasculaire, Métabolisme, Diabétologie et Nutrition, Université Lyon UMR INSERM 1060, France
- INSA Lyon, Hospices Civils
- Kobe University, Japan
- Université de Grenoble U1042 & UMR_S 1055, France
- Université de Rouen UMR INSERM 1096, France
- Yale University, New Haven, CT, USA
We collaborate on an ongoing basis with academic leaders in metabolic disease, cardiovascular disease and mitochondrial dysfunction.
Interested in Collaborating with Us?
We'd love to hear from you and discuss partnership opportunities.